Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC)

Clinica Chimica Acta

Volumn 300, Issue 1-2, 2000, Pages 159-169

  Eissa, Sanaa ^a   Ali Labib, R ^a   Khalifa, A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bladder cancer; Cyclin dependent kinase inhibitors; p15; p16; SCC; Schistosomiasis; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA FRAGMENT; PROTEIN P15; PROTEIN P16;

ADULT; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CELL CULTURE; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHISTOSOMIASIS; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA PRIMERS; GENE DELETION; GENES, P16; HUMANS; POINT MUTATION; POLYMERASE CHAIN REACTION; SCHISTOSOMIASIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0033839469     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00317-X     Document Type: Article

References (27)

1. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibitor of cyclin D/CDK4. Nature. 366:1993;704-707.
2. INK4 the putative tumor supressor gene MTS. Oncogene. 9:1994;3475-3482.
3. INK4. Science. 297:1995;249-252.
4. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshan K., Tavtigian S.V. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
5. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
6. Jen J., Harper J.W., Bigner S.H., Bigner D.D., Papadopulos N., Markowitz S., Willson J.K.V., Kinzer K.W., Vogel Stein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54:1994;6353-6358.
7. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T. In vivo occurrence of p16 (MTSI) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 55:1995;514-517.
8. Mori T., Miura K., Aoki T., Nishihira T., Mon S., Nakamura Y. Frequent somatic mutation of the MTS/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54:1994;3396-3397.
9. Caldas C., Hahn S.A., de Costa L.T., Redston M.S., Schutte M., Seymour A.B. Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinomna. Nat Genet. 8:1994;27-32.
10. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.S., Sheahan M.I.D. Gennline p16 mutations in familial melanoma. Nat Genet. 8:1994;15-21.
11. Kamb A., Liu Q., Harshman K., Tavtigian S., Cordon-cardo C., Skolnick M.H. Rates of p16 (MTSI) mutations in primary tumors with 9p loss. Science. 265:1994;416-417.
12. Cairns P., Merlo A., Lee D.J., Schwab D., Eby Y. Rates of p16 (MTSI) mutations in primary tumors with 9p loss. Science. 265:1994;415-416.
13. Spruck C.H. III, Gonzalez-Zulueta M., Shibata A., Simoneau A.R., Lin M.E., Gonzales F. P16 gene in uncultured tumors. Nature. 370:1994;183-184.
14. Beahrs O.H., Henson D.E., Fluter R.V., et al. Manual for staging of cancer. 4th ed:1992;Lippincott, Philadelphia.
15. Jackson D.P., Hayden J.D., Quirke P. Extraction of nucleic acid from fresh and archival material. McPherson M.J., Quirke P., Taor G.R. PCR: A practical approach. 1991;29-49 Oxford University Press.
16. Southgate J., Proffitt J., Roberts P., Smith B., Selby P. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer. 12:1995;1214-1218.
17. Sanger F., Nicklen S., Coulson A. DNA sequencing with chain-teminating inhibitors. Proc Natl Acad Sci USA. 74:1977;5463-5467.
18. Bissa S., Seada L.S. Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry. Clin Chem. 44:1998;1423-1429.
19. Samnbrook J., Fritsch E.F., Maniatis T. 2nd ed Molecular clonning. Laboratory manual. 18:1989;42-59 Laboratory press, Cold spring Harbor.
20. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Bioch. 72:1976;248-251.
21. Schmidt B.E., Ichimura K., Reifenberger G., Collins P. CDKN2 (p16/MTSI) gene deletion or CDK4 amplification occurs in the majority of glioblastomnas. Cancer Res. 54:1994;6321-6324.
22. Walker D.G., Duan W., Popovic B.A., Kaye A.H., Tomnlinson F.H., Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res. 55:1995;20-23.
23. Gruis N.A., Weaver-Feldhaus J., Liu Q., Frye C., Eeles R., Orlow I. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol. 146:1995;1199-1206.
24. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Melamed J., Zhang Z.F., Sheinfeld J. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 152:1994;388-392.
25. Orlow I., Lacombe L., Hannan G.J., Serrano M., Pellicer I., Dalbagni G., Reuter V.B., Zhang Z.-F., Beach D., Cardon-Cardo C. Deletion of the p16 and p15 Genes in Human Bladder Tumors. J Natl Cancer instit. 87:1995;1524-1529.
26. Tsuzuki T., Tsunoda S., Sakaki T., Konishi N., Hiasa Y., Nakarnura M. Alterations of Retinoblastoma, p513, p16(CDKN2), and p15 Genes in Human Astrocytomas. Cancer. 78:1996;287-293.
27. RB alterations in human urothelial cells. Cancer Res. 55:1995;493-497.